Open AccessP106: Dose intensive brentuximab vedotin for platinum resistant recurrent Hodgkin lymphoma is a feasible treatment option ‐ a single center experience
Author(s) -
Erenmalm Axel,
Linderoth Johan
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000890992.42939.53
Subject(s) - brentuximab vedotin , medicine , refractory (planetary science) , salvage therapy , regimen , surgery , lymphoma , chemotherapy , oncology , hodgkin lymphoma , physics , astrobiology